The Peptide Company
$0.00 0

Cart

No products in the cart.

Continue shopping

ProstaMax : Short Peptide Bioregulator for Prostate Tissue Regulatory Research

ProstaMax short peptide bioregulator molecular structure used in prostate tissue regulatory research

Introduction

Short peptide bioregulators—ultrashort amino acid sequences typically 2–4 residues long—are studied for their ability to influence transcriptional activity, chromatin structure, and intracellular signaling within specific tissues. ProstaMax is a prostate-targeting bioregulator examined for its regulatory interactions with prostate epithelial and stromal tissues, including androgen-associated gene networks, stromal–epithelial signaling, and nuclear regulatory pathways.

Overview of Prostate Tissue Biology

The prostate is composed of luminal epithelial cells, basal epithelial cells, stromal fibroblasts, smooth muscle cells, neuroendocrine cells, and resident immune cells. Regulatory behavior depends heavily on stromal–epithelial cross-talk mediated by growth factors, androgen signaling, cytokines, and extracellular matrix components.

Short Peptide Bioregulators

Bioregulators differ from classical peptides because they act intracellularly rather than through membrane-bound receptors. Their ultrashort size allows passive diffusion, nuclear penetration, and interactions with nuclear proteins, transcription factors, chromatin remodelers, and peptide-binding proteins.

Molecular Basis of ProstaMax

ProstaMax is derived from conserved amino acid motifs found in prostate-regulatory proteins. Its structure allows intracellular and nuclear access, potential affinity for chromatin-associated proteins, androgen receptor co-regulators, nuclear matrix proteins, and DNA-binding proteins.

Mechanistic Pathways

Research explores ProstaMax’s potential influence on transcriptional modulation, chromatin accessibility, androgen-regulated gene networks, MAPK and PI3K/AKT signaling intersections, stromal–epithelial communication pathways, and nuclear scaffold interactions.

Intracellular Transport and Nuclear Uptake

Ultrashort peptides can enter cells through diffusion or transporter-mediated uptake. Once inside, they may bind cytoplasmic proteins, diffuse toward the nucleus, or interact with nuclear import machinery. Due to their size, they may pass through nuclear pores and affect transcriptional protein complexes.

Gene Networks of Interest

Prostate research models investigate ProstaMax in relation to luminal cell markers (PSA/KLK3, TMPRSS2, NKX3-1), basal cell markers (KRT5, KRT14, p63), stromal genes (TGF-β–associated pathways, extracellular matrix remodeling), cytokine expression signatures, and androgen-responsive transcriptional circuits.

Tissue-Level Research Themes

ProstaMax appears in studies examining epithelial differentiation, stromal structural regulation, extracellular matrix turnover, luminal/basal identity markers, prostate-specific secretory genes, and transcriptional homeostasis in androgen-responsive tissues.

Summary

ProstaMax is a prostate-targeting short peptide bioregulator studied for its influence on transcriptional modulation, chromatin structure, stromal–epithelial regulatory pathways, and prostate-specific gene expression. Its ultrashort size and intracellular/nuclear accessibility position it as a unique research tool in prostate regulatory biology.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are made. Compounds referenced are not approved for human use and are intended solely for controlled laboratory research.

PMID:

  • PMID: 11957224 — Tissue-specific regulatory peptides and gene expression control
  • PMID: 15004429 — Short peptides as regulators of transcription and chromatin structure
  • PMID: 15894536 — Peptide regulation of cell differentiation and tissue homeostasis
  • PMID: 17606801 — Prostate-specific peptide signaling and stromal–epithelial interactions

FAQ:

What is ProstaMax studied for in research models?

ProstaMax is studied as a short peptide bioregulator associated with prostate tissue–specific gene expression, stromal–epithelial signaling, and transcriptional regulation in experimental research settings.

How do short peptide bioregulators function at the cellular level?

Short peptide bioregulators are investigated for their ability to influence chromatin structure, transcription factor activity, and intracellular signaling pathways due to their small size and nuclear accessibility.

Is ProstaMax intended for human or clinical use?

No. ProstaMax is referenced exclusively for educational and laboratory research purposes. It is not approved for human use, clinical treatment, or therapeutic applications.

RELATED SEARCHES:

Bronchogen: Short Peptide Bioregulator for Bronchial and Pulmonary Tissue Research

Cardiogen: Short Peptide Bioregulator for Cardiac and Myocardial Tissue Research